Asylia Therapeutics, Houston Texas, Lab

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement

Asylia Therapeutics (“Asylia”), a new, privately-held, development stage biopharmaceutical company, headquartered in Houston at the Texas Medical Center, has finalized an exclusive worldwide license agreement with The University of Texas MD Anderson Cancer Center to develop first-in-class immune modulating therapies for cancer, autoimmune and infectious diseases, which collectively impact tens of millions of Americans annually.   …

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement Read More »